Chinese drug maker Akeso, whose new cancer drug has outperformed a leading Western peer in clinical studies, is being hailed ...

Chinese firms can accelerate clinical trials and bring their drugs to market faster with more supportive policies, ...

Ivonescimab, the new drug, was found in a trial conducted in China to have bested Keytruda, the blockbuster medication ...

Air pollution was cited as a key driver of this type of lung cancer, with the highest levels reported in East Asia, particularly China, the release stated. Worldwide, adenocarcinoma made up more ...

Life science firm Nuvation Bio raised $250 million to bring its novel lung cancer therapy to market and help it reach profitability, the company said Monday.

China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend isn’t confined to Big Tech: It has been quietly happening in the ...

China's national regulator has granted a rapid approval for Roche’s lung cancer treatment Alecensa just months after European and American approvals, following a revamp of the country's ...

When cells of the lung start growing rapidly in an uncontrolled way, the condition is called lung cancer This disease can affect any part of the lung, and it's the leading cause of cancer ...

Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National Medical Products Administration (NMPA) for ...

Kelun-Biotech wins first global regulatory approval - in China - for a TROP2-directed antibody-drug conjugate (ADC) in lung cancer.

A study by researchers from the University of Liverpool and the Research Institute for Diagnostic Accuracy, Netherlands, has ...